Business
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today presented a
About this update from Sab Biotherapeutics, Inc.
[{"type":"image","alt":"SAB Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"SAB Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/e5f8996aaa758da6bd63f582a6d0edc0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xdF3ln07uae4qes6c8cs0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Mg--/https://media.zenfs.com/en/globenewswire.com/e5f8996aaa758da6bd63f582a6d0edc0","width":300,"height":123}},"lazy":false},{"type":"text","content":"All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion","length":168,"tagName":"p"},{"type":"text","content":"T1D participants receiving SAB-142 showed improved glycemic control","length":67,"tagName":"p"},{"type":"text","content":"MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today presented additional clinical and mechanistic data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142 at the 21st Immunology of Diabetes Society (IDS) Congress in Brisbane, Australia.","length":481,"tagName":"p"},{"type":"text","content":"The additional data presented for SAB-142 highlighted C-peptide preservation with a super responder profile among 3 of the 4 participants with T1D, correlated with evidence of CD4+ T conventional (Tconv) cell exhaustion. Other findings presented include improved glycemic control vs baseline based on continuous glucose monitoring (CGM) time in range data.","length":356,"tagName":"p"},{"type":"text","content":"“These new results from the participants with T1D in the Phase 1 trial reinforce SAB-142’s intended mechanism of action, inducing T cell exhaustion that correlates with anticipated C-peptide response levels, and improved glycemic control not driven by exogenous insulin. These findings are consistent with what has been observed with rabbit ATG,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer of SAB BIO. “Importantly, our data demonstrated sustained immunomodulation without immunodepletion with both induction and maintenance ...